Using Electronic Health Records to Predict Mortality Post COPD Hospitalization
For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
For COPD, can electronic health record data predict 90-day post hospitalization mortality — and thereby serve as a risk stratification tool?
Should patients with asthma or COPD have their inhaler regimens switched for nonclinical reasons? A systematic review examined real world evidence on this subject.
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
Does pulmonary inflammation resulting from airborne toxicants trigger immune system activation in individuals with asthma and COPD?
Task force concludes with moderate certainty that there is no net benefit for screening asymptomatic adults for COPD
Which therapy more effectively reduces severe COPD exacerbations: once-daily FF/UMEC/VI or twice-daily ICS/LABA?
Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.
Researchers evaluated the relationship between e-cigarettes and obstructive pulmonary diseases, taking into account age, gender, ethnicity, and body mass index.
Researchers conducted subgroup analysis of revenfenacin phase 3 trial data to assess health status improvements in women vs men with moderate to severe COPD.
The device is attached to the top of the canister of the patient’s inhaler and works together with the mobile app to monitor and provide feedback.